Evaluating the effect of garlic extract on serum inflammatory markers of peritoneal dialysis patients: a randomized double-blind clinical trial study.
Garlic extract
Peritoneal dialysis (PD)
Serum inflammatory markers
Journal
BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793
Informations de publication
Date de publication:
25 01 2019
25 01 2019
Historique:
received:
13
06
2018
accepted:
04
01
2019
entrez:
27
1
2019
pubmed:
27
1
2019
medline:
8
2
2020
Statut:
epublish
Résumé
Garlic can be considered as a useful natural herb in inhibition of inflammation. The aim of this study was to assess the effectiveness of garlic extract in lowering inflammatory markers in peritoneal dialysis (PD) patients. In this parallel-designed double blind randomized clinical trial, 42 PD patients at the Shafa dialysis center, Tehran in 2017 were included. The primary outcome in this study was systemic inflammation which was evaluated by measuring the concentrations of IL-6 and CRP and ESR in serum. Baseline versus after-intervention median (IQR) of IL-6 (pg/ml), CRP (mg/L) and mean ± SD of ESR (mm) in garlic and placebo groups was 2.2 (0.8, 6.4) versus 0.7 (0.6, 1.2) (p < 0.001) and 2.0 (0.8, 2.1) versus 0.6 (0.6, 0.8) (p = 0.002), 13.0 (5.0, 14.0) versus 2.0 (1.0, 9.0) (p < 0.001) and 7.0 (2.0, 10.0) versus 6.0 (3.7, 7.5) (p = 0.547) and 35.4 ± 21.7 versus 50.7 ± 28.5 (p = 0.021) and 46.0 ± 26.0 versus 45.3 ± 22.3 (p = 0.797). Median (IQR) of Percentage Before-After change in CRP was - 71.4%(- 85.7, - 42.9%) and - 20.0%(- 30.0, 114.3%) in garlic and placebo group respectively. The Mann-Whitney U test indicated this difference is statistically significant (p < 0.001). The results imply that administrating 400 mg of standardized garlic extract twice a day for 8 weeks resulted in a significant reduction in IL-6, CRP and ESR. Since inflammatory state can be a serious life threatening condition in PD patients, we suggest prescribing this safe and well-tolerated natural substance to attenuate the inflammatory state in these patients. However, assessment of these effects in a larger randomized trial is strongly recommended (IRCTID: IRCT2017072535305N1, 2017-10-16).
Sections du résumé
BACKGROUND
Garlic can be considered as a useful natural herb in inhibition of inflammation. The aim of this study was to assess the effectiveness of garlic extract in lowering inflammatory markers in peritoneal dialysis (PD) patients.
METHODS
In this parallel-designed double blind randomized clinical trial, 42 PD patients at the Shafa dialysis center, Tehran in 2017 were included. The primary outcome in this study was systemic inflammation which was evaluated by measuring the concentrations of IL-6 and CRP and ESR in serum.
RESULTS
Baseline versus after-intervention median (IQR) of IL-6 (pg/ml), CRP (mg/L) and mean ± SD of ESR (mm) in garlic and placebo groups was 2.2 (0.8, 6.4) versus 0.7 (0.6, 1.2) (p < 0.001) and 2.0 (0.8, 2.1) versus 0.6 (0.6, 0.8) (p = 0.002), 13.0 (5.0, 14.0) versus 2.0 (1.0, 9.0) (p < 0.001) and 7.0 (2.0, 10.0) versus 6.0 (3.7, 7.5) (p = 0.547) and 35.4 ± 21.7 versus 50.7 ± 28.5 (p = 0.021) and 46.0 ± 26.0 versus 45.3 ± 22.3 (p = 0.797). Median (IQR) of Percentage Before-After change in CRP was - 71.4%(- 85.7, - 42.9%) and - 20.0%(- 30.0, 114.3%) in garlic and placebo group respectively. The Mann-Whitney U test indicated this difference is statistically significant (p < 0.001).
CONCLUSION
The results imply that administrating 400 mg of standardized garlic extract twice a day for 8 weeks resulted in a significant reduction in IL-6, CRP and ESR. Since inflammatory state can be a serious life threatening condition in PD patients, we suggest prescribing this safe and well-tolerated natural substance to attenuate the inflammatory state in these patients. However, assessment of these effects in a larger randomized trial is strongly recommended (IRCTID: IRCT2017072535305N1, 2017-10-16).
Identifiants
pubmed: 30683061
doi: 10.1186/s12882-019-1204-6
pii: 10.1186/s12882-019-1204-6
pmc: PMC6347806
doi:
Substances chimiques
Biomarkers
0
IL6 protein, human
0
Interleukin-6
0
Lipids
0
Plant Extracts
0
alliin
7I4L2D0E9G
C-Reactive Protein
9007-41-4
Cysteine
K848JZ4886
Banques de données
IRCT
['IRCT2017072535305N1']
Types de publication
Comparative Study
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
26Références
Arthritis Res Ther. 2009;11(5):R145
pubmed: 19788760
J Hypertens. 1994 Apr;12(4):463-8
pubmed: 8064171
J Diet Suppl. 2012 Dec;9(4):262-71
pubmed: 23039014
Mediators Inflamm. 2013;2013:381815
pubmed: 24453416
Int J Nephrol. 2014;2014:909373
pubmed: 24895536
Am J Clin Nutr. 2006 Dec;84(6):1324-9
pubmed: 17158412
Cytometry. 2002 Aug 1;48(4):209-15
pubmed: 12210145
BMC Cardiovasc Disord. 2008 Jun 16;8:13
pubmed: 18554422
J Med Food. 2012 Nov;15(11):992-9
pubmed: 23057778
Ann Pharmacother. 2008 Dec;42(12):1766-71
pubmed: 19017826
Adv Chronic Kidney Dis. 2005 Jul;12(3):292-9
pubmed: 16010644
Nutr Metab (Lond). 2011 Jul 27;8:53
pubmed: 21794123
J Nutr. 2009 Nov;139(11):2055-60
pubmed: 19759245
Semin Nephrol. 2017 Jan;37(1):54-65
pubmed: 28153195
Comp Biochem Physiol A Mol Integr Physiol. 2003 Aug;135(4):539-47
pubmed: 12890544
Curr Diabetes Rev. 2013 Sep;9(5):402-11
pubmed: 23865416
Anticancer Agents Med Chem. 2014 Feb;14(2):233-40
pubmed: 24237225
Nutr Rev. 2017 Sep 1;75(9):731-767
pubmed: 28938795
Planta Med. 2015 Aug;81(12-13):975-94
pubmed: 26132858
Prim Care Diabetes. 2019 Feb;13(1):28-42
pubmed: 30049636
Contrib Nephrol. 2017;191:32-43
pubmed: 28910789
J Am Soc Nephrol. 2012 Mar;23(3):533-44
pubmed: 22302194
Nutr Res Rev. 2009 Jun;22(1):39-48
pubmed: 19555517
Food Chem Toxicol. 2008 Feb;46(2):619-27
pubmed: 17950512
J Nutr Metab. 2011;2011:475216
pubmed: 21876795
J Nutr. 2016 Feb;146(2):389S-396S
pubmed: 26764326
Kidney Int. 2003 Mar;63(3):793-808
pubmed: 12631061
Stat Methods Med Res. 2016 Jun;25(3):1057-73
pubmed: 26092476